Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Lars G Svensson Added: 3 years ago
If you can look into the seeds of time and say which grain will grow and which will not speak then to me. Macbeth; William Shakespeare. Predictions of the role of transcatheter aortic valve replacement (TAVR) in moderate-risk patients is fraught with potential pitfalls. The matrix of outcomes is interlinked and changes in one cell may have consequences beyond currently observable measures. For… View more
Author(s): Florian Hecker , Mani Arsalan , Thomas Walther Added: 3 years ago
Transcatheter aortic valve replacement (TAVR) has become the default treatment option for high-risk patients with aortic stenosis (AS) and, based on heart team discussion, an alternative to surgical aortic valve replacement (SAVR) in intermediate-risk patients. TAVR has led to a paradigm shift in the basic therapeutic principle to treat AS: calcifications, in some patients quite excessive, are… View more
Author(s): Hellmuth Weich Added: 3 years ago
There has been a recent explosion in the field of transcatheter aortic and pulmonary valve replacements, but the atrio-ventricular valves have lagged behind for various reasons with the tricuspid valve undoubtedly the least treated valve of the four. Despite the fact that tricuspid regurgitation (TR) can result in significant symptoms, patients are rarely referred for isolated surgical tricuspid… View more
Author(s): Lutz Buellesfeld , Ulrich Gerckens Added: 3 years ago
Surgical aortic valve replacement is the reference standard for patients with symptomatic severe aortic valve stenosis.1,2 Despite the fact that the prognosis with medical management is poor, many patients do not undergo surgery due to an increased anticipated operative risk, driven by co-morbidities such as pulmonary hypertension, severe obstructive pulmonary disease, previous cardiac surgery,… View more
Author(s): Thomas Walther , Johannes Blumenstein Added: 3 years ago
During the past five years, transcatheter (T) aortic valve implantation (AVI) has evolved as one of the most important clinical innovations in cardiovascular disease. The specific merit of TAVI is to allow for minimally invasive treatment of severe symptomatic aortic stenosis (AS) in elderly and high-risk patients. Since 2005 retrograde transfemoral (TF) and antegrade transapical (TA) aortic… View more
Author(s): Shu-I Lin , Mizuki Miura , Ana Paula Tagliari , et al Added: 3 years ago
Transcatheter aortic valve implantation (TAVI) is now established as the standard treatment for symptomatic severe aortic stenosis (AS) in patients at high or prohibitive surgical risk, and the preferred treatment for those at intermediate risk.1 Based on recent trials in low-risk patients, the indications for TAVI are expanding towards the lower-risk classes, and the procedure has even been… View more
Author(s): Victoria Delgado , See Hooi Ewe , David Messika-Zeitoun , et al Added: 3 years ago
Since the first-in-man experience by Cribier and co-workers,1 transcatheter aortic valve implantation (TAVI) has rapidly evolved, providing a feasible therapeutic alternative for patients with severe symptomatic aortic stenosis who have high-risk or contraindications to conventional surgery. The promising results of TAVI procedures reported by various registries2–6 were recently confirmed in the… View more